<!doctype html>
<html lang="en">
<head>
    <meta charset="utf-8" />
    <title>DexTech Medical</title>
    <meta name="viewport" content="width=device-width, initial-scale=1.0" />

    <!-- 1140px Grid styles and HTML5-Shiv for IE -->
    <!--[if lte IE 9]>
    <link rel="stylesheet" href="css/ie.css" type="text/css" media="screen" />
    <script src="//html5shiv.googlecode.com/svn/trunk/html5.js"></script>
    <![endif]-->

    <!-- The 1140px Grid - http://cssgrid.net/ -->
    <link rel="stylesheet" href="css/1140.css" type="text/css" media="screen" />
    <link rel="stylesheet" href="css/styles.css" type="text/css" media="screen" />

    <!--css3-mediaqueries-js - http://code.google.com/p/css3-mediaqueries-js/ - Enables media queries in some unsupported browsers-->
    <script type="text/javascript" src="js/css3-mediaqueries.js"></script>
</head>
<body>
    <header class="container">
        <div class="row">
            <div class="twelvecol last">
                <img id="abstract" src="img/header_abstracts.png" alt="" />
                <h1>
                    <img src="img/logo.png" alt="DexTech"/>
                </h1>
                <span>Know-how in Translational Research</span>
            </div>
        </div>
    </header>

    <div class="container" id="main">
        <div class="row">
            <div class="sixcol">
                <h2>About us</h2>
                <p>DexTech develops drug candidates for urologic oncology, especially prostate cancer, based on glycosylation engineering.</p>
                <p>Close connection between R&amp;D and clinical oncology ensures development of tools for real clinical problems.</p>
                <p>DexTech was established in 2004 by:</p>

                <ul>
                    <li><span class="highlight">Anders R Holmberg</span>, a chemical engineer with a PhD in experimental oncology. He is an expert in glycosylation chemistry.</li>
                    <li><span class="highlight">Sten Nilsson (MD, PhD)</span>, a specialist in clinical oncology (urologic oncology, especially prostate cancer).</li>
                </ul>

                <p>Anders R Holmberg is managing director and Sten Nilsson is our clinical expert and member of the board.</p>
            </div>

            <div class="sixcol last" id="illustration">
                <img src="/img/illustration.png" alt=""/>
            </div>
        </div>

        <div class="row">
            <div class="sixcol">
                <h2>Contact</h2>
                <h3>Visiting Address</h3>
                <address>
                    Birger Jarlsgatan 41A, SE-111 45,
                    Stockholm, Sweden.
                </address>

                <h3>Postal Address</h3> 
                <address>Box 119, SE-75104 Uppsala, Sweden.</address>

                <h3>Telephone & Email</h3>
                <p>+46.8.613 1304 (Mr Kanekrans), <br>
                <a href="mailto:arh@telia.com">arh@telia.com</a> (Anders R Holmberg).</p>

                <h3>Investor Relations</h3>
                <p>
                    Mr Peter Kanekrans: +46.8.613 1304, <a href="mailto:peter.kanekrans@dextechmedical.com">peter.kanekrans@dextechmedical.com</a>.
                </p>
            </div>
            <div class="sixcol last">
                <h2>Drug candidates</h2>
                <p><span class="highlight">CatDex</span>, for instillation therapy of superficial bladder cancer (pre-clinical stage), </p>
                <p><span class="highlight">SomaDex</span>, for palliative treatment of advanced prostate cancer (out licensed, <a href="http://www.techsphere.com.mx">TechSphere Corp.</a>, Mexico, in phase2)</p>
                <p><span class="highlight">OsteoDex</span>, for treatment of bone metastasis in advanced prostate cancer (<a href="http://clinicaltrials.gov/ct2/show/NCT01595087?term=odx&rank=1">phase1-2a, in progress</a>)</p>
                <p>IPR is protected by a family of three world wide applied patents/applications including China and India.</p>
            </div>
        </div>

        <div class="row">
            <div class="twelvecol last">
                <h2>Partners and Network</h2>
            </div>
            <div class="threecol">
                <h3>Europe</h3>
                <ul>
                    <li>Helsinki University Hospital, Finland</li>
                    <li>European Institute of Oncology, Milan, Italy</li>
                    <li>Ångströmlab, Uppsala University, Sweden</li>
                    <li>Atlantic Bone Screen, Nantes, France</li>
                    <li>PharmaPlus Consultancy, The Netherlands</li>
                    <li>University Trás-os-Montes och Alto Douro, Vila Real, Portugal</li>
                </ul>
            </div>
            <div class="threecol">
                <h3>Middle East/Asia</h3>
                <ul>
                    <li>King Feisal Research Center, Ryijad, Saudi Arabia</li>
                    <li>The Weizmann Institute of Science, Israel</li>
                    <li>Shandong University Hospital, Shandong, China</li>
                    <li>Beijing Univ., Beijing, China</li>
                </ul>
            </div>
            <div class="threecol">
                <h3>North America</h3>
                <ul>
                    <li>Sloan Kettering Memorial Cancer Center, New York, USA</li>
                    <li>UANL, Monterrey, Mexico</li>
                    <li>UDEM/Mougerza Hospitals, Monterrey, Mexico</li>
                    <li>TechSphere Corp. Mexico City, Mexico</li>
                </ul>
            </div>
            <div class="threecol last">
                <h3>South-America</h3>
                <ul>
                    <li>Ipiranga University Hospital, Sao Paolo, Brazil</li>
                </ul>
            </div>
        </div>

        <div class="row" id="related_publications">
            <div class="twelvecol last">
                <h2>Selection of Related Publications</h2>
                <ol>
                    <li><a href="http://np.netpublicator.com/netpublication/n08729614">The hunt for new treatments</a>. Holmberg A. R. Prostate Cancer report in The Times newspaper, 02 December 2008</li>
                    <li><a href="http://np.netpublicator.com/netpublication/n32395664">Bones and prostate cancer</a>. Holmberg A. R. Prostate Cancer report in The Times newspaper, 28 October 2009</li>
                    <li><a href="http://www.ncbi.nlm.nih.gov/pubmed/11877759">A novel somatostatin conjugate with high affinity to all five somatostatin receptor subtypes</a>. U. Wulbrand, M. Feldman, A. Pfestroff, H-C. Fehman, J. Du, J. Hiltunen, M. Marquez, S. Arnold R., Westlin J.E., Nilsson, and A. R. Holmberg. Cancer. 94; 4:1293-1297. Feb 15, 2002.</li>
                    <li><a href="http://www.ncbi.nlm.nih.gov/pubmed/15650261">Phase I trial on sms-D70 somatostatin analogue in advanced prostate and renal cell cancer</a>. Joensuu T.K., Nilsson S, Holmberg A.R., Marquez M, Tenhunen M, Saarto T and Jeonsuu H. Ann. N.Y. Acad Sci.1028:361-371, 2004.</li>
                    <li><a href="http://np.netpublicator.com/netpublication/n99233373">When prostate cancer becomes incurable</a>. Holmberg A.R. Prostate Cancer report in The Times newspaper, 26 October 2010</li>
                    <li><a href="http://www.ncbi.nlm.nih.gov/pubmed/22199272">Treatment of bone metastasis in prostate cancer: efficacy of a novel polybisphosphonate</a>. Daubine F, LE Bot R, Márquez M, Nilsson S, Schröder T, Holmberg AR. Andticancer Research 31:4141-4146, 2011.</li>
                    <li><a href="http://www.ncbi.nlm.nih.gov/pubmed/17390019">Somatostatin effects on the proteome of the LNCaP cell-line</a>. Zhaoxu Liu, Sofia Bengtsson, Morten Krogh, Marcela Marquez, Sten Nilsson, Peter James, Ayodele Aliaya, and Anders R. Holmberg. Int. J. Oncology, 2007.</li>
                    <li><a href="http://www.ncbi.nlm.nih.gov/pubmed/19578741">Polymer-conjugated guanidine is a potentially useful anti-tumor agent</a>. Meurling L, Márquez M, Nilsson S and Holmberg AR. Int J Oncol 35: 281-285, 2009.</li>
                    <li><a href="http://www.ncbi.nlm.nih.gov/pubmed/20664925">Development of a Novel Poly Bisphosphonate Conjugate for Treatment of Skeletal Metastasis and Osteoporosis</a>. Anders R. Holmberg, Ulf H. Lerner, Ayodele Alyia, Mai Al-Mohanna, Chaker Adra, Marcela Marquez, Lennart Meurling, and Sten Nilsson. Int J Oncology, 37, 563-567, 2010.</li>
                    <li><a href="http://www.ncbi.nlm.nih.gov/pubmed/21818805">Application of accelerator mass spectrometry to macromolecules: preclinical pharmacokinetic studies on a polybisphosphonate</a>. Mehran Salehpour, Karl Håkansson, Urban Höglund, Annika Grahn-Westin, Sten Nilsson, Marcela Márquez, Göran Possnert and Anders R. Holmberg. Rapid Commun. Mass Spectrom. 25, 2453–2458, 2011.</li>
                </ol>
            </div>
        </div>
    </div>

    <footer class="container">
        <div class="row">
            <div class="twelvecol last">
                <address>
                    Birger Jarlsgatan 41A, 111 45 Stockholm, Sweden.
                </address>
                <img id="footer_logo" src="img/footer_logo.png" alt="DexTech Medical AB" />
                <img id="footer_abstract" src="img/footer_abstract.png" alt="DexTech Medical AB" />
            </div>
        </div>
    </footer>
</body>
</html>
